UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

Haematologica (Roma), 2012-02, Vol.97 (2), p.213-218

2012

Volltextzugriff (PDF)

Is this really thalassemia?

American journal of hematology, 2023-11, Vol.98 (11), p.1814-1815

2023

Volltextzugriff (PDF)

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Blood, 2021-11, Vol.138 (Supplement 1), p.1201-1201

2021

Volltextzugriff (PDF)

Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients

American journal of hematology, 2020-11, Vol.95 (11), p.1314-1323

2020

Volltextzugriff (PDF)

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Blood, 2018-11, Vol.132 (Supplement 1), p.1774-1774

2018

Volltextzugriff (PDF)

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

British journal of haematology, 2019-12, Vol.187 (5), p.615-626

2019

Volltextzugriff (PDF)

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Blood, 2017-12, Vol.130, p.2918-2918

2017

Volltextzugriff (PDF)

PICALM–MLLT10 acute myeloid leukemia: A French cohort of 18 patients

Leukemia research, 2012-11, Vol.36 (11), p.1365-1369

2012

Volltextzugriff (PDF)

From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia

Annales de biologie clinique (Paris), 2017-12, Vol.75 (6), p.689-694

2017

Volltextzugriff (PDF)

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

Leukemia research, 2011-11, Vol.35 (11), p.1444-1448

2011

Volltextzugriff (PDF)

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Blood, 2012-11, Vol.120 (21), p.422-422

2012

Volltextzugriff (PDF)

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Blood, 2011-11, Vol.118 (21), p.972-972

2011

Volltextzugriff (PDF)

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program

Blood, 2009-11, Vol.114 (22), p.2764-2764

2009

Volltextzugriff (PDF)

Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program

Blood, 2009-11, Vol.114 (22), p.1054-1054

2009

Volltextzugriff (PDF)

Is this really thalassemia?

American journal of hematology, 2023, Vol.98 (11), p.1814-1815

2023

Volltextzugriff (PDF)

Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation

Bio-medical materials and engineering, 2012, Vol.22 (1-3), p.57

2012

Volltextzugriff (PDF)

CALM-AF10 Positive Acute Myeloid Leukemias: A French Cohort of 18 Patients

Blood, 2008-11, Vol.112 (11), p.1496-1496

2008

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Current Content Access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(26)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(10)
Life Sciences & Biomedicine
(9)
Hematology
(8)
Humans
(8)
Male
(8)
Adult
(7)
Female
(7)
Middle Aged
(7)
Aged
(6)
Adolescent
(4)
Aged, 80 And Over
(4)
Treatment Outcome
(4)
Young Adult
(4)
Antineoplastic Agents - Therapeutic Use
(3)
Oncogene Proteins, Fusion - Genetics
(3)
Oncology
(3)
Patients
(3)
Acute Myeloid Leukemia
(2)
Antineoplastic Agents - Adverse Effects
(2)
Biological And Medical Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(15)
American Journal Of Hematology
(2)
British Journal Of Haematology
(2)
Leukemia Research
(2)
Annales De Biologie Clinique
(1)
Bio-Medical Materials And Engineering
(1)
Genes Chromosomes & Cancer
(1)
Haematologica
(1)
Hématologie
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

Is this really thalassemia?

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

PICALM–MLLT10 acute myeloid leukemia: A French cohort of 18 patients

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM)

Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program

Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program

Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program

Is this really thalassemia?

Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation

CALM-AF10 Positive Acute Myeloid Leukemias: A French Cohort of 18 Patients

Treatment of Lower Risk MDS with Del 5q by Lenalidomide, with or without G-CSF: Current Results of the French Patient Named Program (ATU)

Aktive Filter

Suchergebnisse filtern